WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA Therapeutics today announced the appointment of Paolo Paoletti, M.D., former President, GlaxoSmithKline (GSK) Oncology, to the company’s Board of Directors. In addition to serving as a director, Dr. Paoletti will also lead FORMA’s Research & Development Committee as its chairperson; in this capacity, his strategic clinical and research insights will be applied to FORMA’s target family drug discovery paradigm.
Dr. Paoletti held several executive leadership roles in oncology at GSK, including Head of Oncology R&D Unit, Member of the Executive Board for Portfolio Investment and Chairman of the Oncology Portfolio Board. In his global leadership roles, he maintained the accountability for GSK’s entire oncology business and was responsible for drug discovery from target identification through registration, including product life cycle management and commercial strategy.
Throughout his pharmaceutical tenure at GSK, he led the global approval of seven new medicines to treat different cancers, originated a global oncology business integrating regional plans and responsibilities, and led the development of the first novel–novel combination of agents to registration with the FDA.
“Paolo’s contributions in oncology and his direct impact on human health are nothing short of unparalleled excellence. He championed seven new medicines for cancer patients in 10 years, and his proven expertise in building a top class development organization, in an unprecedented way, is a testament to his innovative and solutions-oriented perspective,” said Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics. “Placing the patient front and center aligns our R&D team with a shared purpose to develop medicines that make a profound difference. Paolo’s global insights, expertise in obtaining differentiated, reimbursable and promotable files, and emphasis on translational medicine in oncology will provide FORMA with ideal expertise and perspective as we advance an extensive portfolio of candidates into clinical trials.”
“I am honored to join FORMA’s Board of Directors at this very exciting time,” said Dr. Paoletti. “The novelty and quality of FORMA’s discovery and pre-clinical activities of the past years have been excellent and, now, emphasize the rapid translation of this science into the clinic. The deep understanding gained from employing a target family discovery approach and the related clinical candidates in development for such qualified targets are extremely interesting and innovative. I am confident that these highly differentiated medicines will be accelerated in the clinic and tailored to address patient needs.”
Prior to joining GSK Oncology in 2004, Dr. Paoletti served in roles of increasing leadership responsibility at Eli Lilly in Indianapolis, where he was most recently Vice President, Oncology. He received his M.D. from University of Pisa, Italy, and he was a NIH Fogarty fellow at the University of Arizona. Dr. Paoletti has authored over 350 scientific publications.
FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology and other genetically driven therapeutic areas. The company's drug discovery engine drives screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions. Deep biological insight across targets is combined with the company's chemistry expertise and integrated with a world class network of academic investigators, clinical experts and corporate partners to rapidly direct the creation of high quality, innovative drug candidates.
FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with additional chemistry operations in Branford, CT. www.formatherapeutics.com
Join our conversation on Twitter @FORMAInc.